Morgan Stanley Call 310 AMG 20.12.../ DE000MB16YN7 /
2024-06-24 3:55:00 PM | Chg.0.00 | Bid4:17:39 PM | Ask4:17:39 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
2.62EUR | 0.00% | 2.71 Bid Size: 20,000 |
2.74 Ask Size: 20,000 |
AMGEN INC. DL-... | 310.00 - | 2024-12-20 | Call |
GlobeNewswire
06-20
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7...
GlobeNewswire
06-19
Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors
GlobeNewswire
06-18
CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Confere...
GlobeNewswire
06-17
FDA Approves Phase II Clinical Trial for Ruxoprubart in ANCA Associated Vasculitis (AAV) – a Chronic...
GlobeNewswire
06-17
Solid Power Appoints Renewables Industry Veteran Linda Heller as Chief Financial Officer
GlobeNewswire
05-30
Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affa...
GlobeNewswire
05-28
Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD
GlobeNewswire
05-27
Samsung Bioepis Announces Oral Presentation on Switching Period Results for SB16, a Proposed Biosimi...
GlobeNewswire
05-23
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine recept...
GlobeNewswire
05-22
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilar...
GlobeNewswire
05-21
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
GlobeNewswire
05-21
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a bios...
GlobeNewswire
05-15
Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member
GlobeNewswire
05-14
Accumulus Synergy Sponsors Revolutionary Healthcare Data Standard, Advancing Towards Global Dossier
GlobeNewswire
05-14
Nouscom Appoints Leading Cancer Drug Development Expert, Neil Gallagher, MD, PhD, as Independent Adv...